Answers are grounded in this paper and cite their sources.
Hypoxia-inducible factor-1 (HIF-1) plays important roles in regulating radiosensitivity, making it a potentially promising target for tumour radiosensitisation. Here, we discuss the rationale for, and the potential pitfalls of, combining HIF-1 blockade with radiotherapy. In doing so, we describe clinical scenarios in which HIF-1 inhibition might optimise tumour radiosensitivity.
No takes yet. Share an insight, caveat, or question.
Moeller et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: